产品
编 号：F279351
分子式：C30H32F2N4O3
分子量：534.6
分子式：C30H32F2N4O3
分子量：534.6
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 2222941-37-7
产品详情
生物活性：
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a Kd of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression.
体内研究：
Inobrodib (10-30 mg/kg; oral gavage; 10 or 20 mg/kg daily (QD) or 30 mg/kg every other day (QOD) for 28 days) 抑制 22Rv1 小鼠异种移植模型的生长，并伴有 AR 减少信号。 Inobrodib (20 mg/kg; oral gavage; daily for 8 days) 减少 AR 和 AR-V7 信号并抑制患者来源的致死性前列腺肿瘤模型的肿瘤生长。Animal Model:Noncastrated male athymic nude mice
Dosage:10-30 mg/kg
Administration:Oral gavage; at 10 or 20 mg/kg daily (QD) or at 30 mg/kg every other day (QOD) for 28 days
Result:Affected tumor growth at 10 mg/kg daily, 20 mg/kg daily, and 30 mg/kg every other day.
体外研究：
Inobrodib 在细胞内 BRET 测定中与细胞组蛋白结合，对 p300 的 IC50 为 19 nM，对 BRD4 的 IC50 为 1060 nM。Inobrodib 在表达 AR-FL 和 AR-V7 的 VCaP、22Rv1 和 LNCaP95 (IC50 均 Inobrodib 相关抗体:
Inobrodib (CCS1477) is an orally active, potent, and selective inhibitor of the p300/CBP bromodomain. Inobrodib binds to p300 and CBP with Kd values of 1.3 and 1.7 nM, respectively, and with 170/130-fold selectivity compared with BRD4 with a Kd of 222 nM. CCS1477 inhibits cell proliferation in prostate cancer cell lines and decreases androgen receptor (AR)- and C-MYC-regulated gene expression.
体内研究：
Inobrodib (10-30 mg/kg; oral gavage; 10 or 20 mg/kg daily (QD) or 30 mg/kg every other day (QOD) for 28 days) 抑制 22Rv1 小鼠异种移植模型的生长，并伴有 AR 减少信号。 Inobrodib (20 mg/kg; oral gavage; daily for 8 days) 减少 AR 和 AR-V7 信号并抑制患者来源的致死性前列腺肿瘤模型的肿瘤生长。Animal Model:Noncastrated male athymic nude mice
Dosage:10-30 mg/kg
Administration:Oral gavage; at 10 or 20 mg/kg daily (QD) or at 30 mg/kg every other day (QOD) for 28 days
Result:Affected tumor growth at 10 mg/kg daily, 20 mg/kg daily, and 30 mg/kg every other day.
体外研究：
Inobrodib 在细胞内 BRET 测定中与细胞组蛋白结合，对 p300 的 IC50 为 19 nM，对 BRD4 的 IC50 为 1060 nM。Inobrodib 在表达 AR-FL 和 AR-V7 的 VCaP、22Rv1 和 LNCaP95 (IC50 均 Inobrodib 相关抗体:
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备